• Publications
  • Influence
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth
PURPOSE The objective of this study was to determine whether the addition of trastuzumab to chemotherapy in the neoadjuvant setting could increase pathologic complete response (pCR) rate in patientsExpand
  • 1,006
  • 33
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
PURPOSE ABI-007 is a novel Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. The absence of Cremophor EL may permit ABI-007 to be administered without the premedicationsExpand
  • 558
  • 17
  • PDF
Defining prognosis for women with breast cancer and CNS metastases by HER2 status.
BACKGROUND The purpose of this retrospective study was to determine, in a cohort of patients with breast cancer and central nervous system (CNS) metastases, the effect of trastuzumab in patients withExpand
  • 158
  • 14
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
PURPOSE To determine the impact a change in schedule of paclitaxel administration from once every 3 weeks to frequent administration would have on the pathologic complete response (pCR) rate in theExpand
  • 370
  • 10
Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer
Purpose: We examined in a prospective, randomized, international clinical trial the performance of a previously defined 30-gene predictor (DLDA-30) of pathologic complete response (pCR) toExpand
  • 166
  • 10
  • PDF
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.
PURPOSE ABI-007 is a novel nanoparticle, albumin-bound paclitaxel that is free of solvents. This multicenter phase II study was designed to evaluate the efficacy and safety of ABI-007 for theExpand
  • 217
  • 7
CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
Deregulation of the cell cycle machinery is a hallmark of cancer. While CDK4/6 inhibitors are FDA approved (palbociclib) for treating advanced estrogen receptor-positive breast cancer, two majorExpand
  • 102
  • 7
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
PURPOSE Paclitaxel has significant antitumor activity in patients with metastaticbreast cancer who have been previously treated with or exposed to anthracycline-containing chemotherapy. In thisExpand
  • 167
  • 6
  • PDF
Breast cancer metastasis to the central nervous system
As breast cancer patients live longer, the development of central nervous system (CNS) metastases has become more prevalent. Clinically symptomatic breast cancer metastasis to the CNS is associatedExpand
  • 112
  • 4
The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy.
PURPOSE To quantify the impact of immediate breast reconstruction on postmastectomy radiation therapy (PMRT) planning. METHODS A total of 110 patients (112 treatment plans) who had mastectomy withExpand
  • 155
  • 3